Ena Respiratory
ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for the prophylaxis of respiratory viral infections, including COVID-19, rhinovirus and influenza in populations at risk of complications. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
CAD113—169m (Dealroom.co estimates Jun 2021.)
Sydney New South Wales (HQ), Melbourne Victoria (founding location)
Authorizing premium user...